Phase I clinical and pharmacokinetic study of PK1 [N-(2- hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents - Drug-polymer conjugates

Clinical Cancer Research

Volumn 5, Issue 1, 1999, Pages 83-94

  Vasey, Paul A ^a   Kaye, Stan B ^a   Morrison, Rosemary ^a   Twelves, Chris ^a   Wilson, Peter ^a   Duncan, Ruth ^b   Thomson, Alison H ^c   Murray, Lilian S ^c   Hilditch, Tom E ^c   Murray, Tom ^c   Burtles, Sally ^d   Fraier, D ^e   Frigerio, E ^e   Cassidy, Jim ^f  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e Bioanalytical Laboratory   (Italy)

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; FCE 28068; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; PK 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG RESISTANCE; DRUG UPTAKE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; MUCOSA INFLAMMATION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG CARRIERS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; POLYMETHACRYLIC ACIDS;

EID: 0032959549     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Benjamin, R. S. Pharmacokinetics of Adriamycin in patients with sarcomas. Cancer Chemother. Rep., 58: 271-273, 1974.
2. Newell, D. R. Pharmacokinetic determinants of activity and toxicity of antitumour agents. Cancer Surv., 8: 557-603, 1989.
3. Cassidy, J., Newell, D. R., Wedge S. R., and Cummings, J. Pharmacokinetics of high molecular weight agents. Cancer Surv., 17: 315-341, 1993.
4. Duncan, R., Dimitrijevic, S., and Evagorou, E. G. The role of polymer conjugates in the diagnosis and treatment of cancer. STP Pharm. Sci., 6: 237-263, 1996.
5. DelaFlor-Weiss, E., Uziely, B., and Muggia, F. M. Protracted drug infusions in cancer treatment: An appraisal of 5-fluorouracil, doxorubicin and platinums. Ann. Oncol., 4: 723-733, 1993.
6. Trouet, A., and Joules, G. Targeting of daunomycin by association with DNA or proteins: a review. Semin. Oncol., 64: 64-72, 1984.
7. Scheeter, B., Neumann, A., and Wilchek, M. Soluble polymers as carriers of cisplatinum. J. Controlled Release, 10: 75-87, 1989.
8. Levi-Schaffer, F., Bernstein, A., and Mesnorer, A. Reduced toxicity of daunorubicin by conjugation to dextran. Cancer Treat. Rep., 6: 107-114, 1982.
9. Trouet, A., Masquelier, M., and Baurain, R. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for lysosomotropic drug carrier conjugate: in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA, 79: 626-629, 1982.
10. Seymour, L. W. Passive tumour targeting of soluble macromolecules and drug conjugates. CRC Crit. Rev. Ther. Drug Carrier Syst., 9: 135-187, 1992.
11. Matsumura, Y., and Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy; mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res., 6: 6387-6392, 1987.
12. Maeda, H., and Matsumura, Y. Tumouritropic and lymphotropic principles of macromolecular drugs. CRC Crit. Rev. Ther. Drug Carrier Syst., 6: 193-210, 1989.
13. Duncan, R., Kopeckova-Rejmanova, P., Strohalm, J., Hume, I., Cable, H. C., Pohl, J., Lloyd, J. B., and Kopecek, J. Anticancer agents coupled to [N-(2-hydroxypropyl)methacrylamide] copolymers. 1. Evaluation of daunomycin and puromycin conjugates in vitro. Br. J. Cancer, 55: 165-174, 1987.
14. Banker, G. S. Pharmaceutical applications of controlled release: an overview of the past, present and the future. In: R. S. Langer, and D. L. Wise (eds.), Medical Applications of Controlled Release, Vol. 2, pp. 1-34. Boca Raton, FL: CRC Press, 1984.
15. DeDuve, C., De Barsy, T., and Poole, B. Lysosomotropic agents. Biochem. Pharmacol., 23: 2495-2531, 1974.
16. Kartner, N., Evernden-Porelle, D., Bradley, G., and Ling, V. Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature (Lond.), 316: 820-823, 1985.
17. Ringsdorf, H. Structures and properties of pharmacologically active polymers. J. Polymer Sci. Polymer Symp., 51: 135-153, 1975.
18. Duncan, R. Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs, 3: 175-210, 1992.
19. Kopecek, J., and Bazilova, H. Poly[W-(hydroxypropyl)-methacrylamide]-1. Radical polymerisation and copolymerisation. Eur. Polymer J., 9: 7-14, 1973.
20. Rihova, B., and Kopecek, J. Biological properties of targetable poly[N-(2-hydroxypropyl)methacrylamide)-antibody conjugates. J. Controlled Release, 2: 289-310, 1985.
21. Rihova, B., Ulbrich, J., Strohalm, J., Vetvicka, V., Bilej, M., Duncan, R., and Kopecek, J. Biocompatibility of [N-(2-hydroxypropyl) methacrylamide) copolymers containing Adriamycin. Immunogenicity, effect of haematopoietic stem cells in bone marrow in vivo and effect on mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials, 10: 335-342, 1989.
22. Rejmanova, P., Kopecek, J., Duncan, R., and Lloyd, J. B. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide) copolymers. Biomaterials, 6: 45-48, 1985.
23. Cassidy, J., Duncan, R., Morrison, G. J., Strohalm, J., Plocova, D., Kopecek, J., and Kaye, S. B. Activity of [N-(2-hydroxypropyl)methacrylamide) co-polymers containing daunomycin against a rat tumour model. Biochem. Pharmacol., 38: 875-879, 1989.
24. Seymour, L. W., Ulbrich, K., Steyger, P. S., Brereton, M., Subr, V., Strohalm, J., and Duncan, R. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer, 70: 636-641, 1994.
25. Duncan, R., Cable, H. C., Lloyd, J. B., Rejmanova, P., and Kopecek, J. Degradation of side-chains of W-(2-hydroxypropyl)methacrylamide) copolymers by lysosomal thiolproteinases. Biosci. Rep., 2: 1041-1046, 1982.
26. Seymour, L. W., Ulbrich, K., Strohalm, J., Kopecek, J., and Duncan, R. Pharmacokinetics of polymer-bound Adriamycin. Biochem. Pharmacol., 39: 1125-1131, 1990.
27. Minko, T., Kopeckova, P., Pozharov, V., and Kopecek, J. HPMA copolymer bound Adriamycin overcomes MDR1 gene encoded resist-ance in a human ovarian carcinoma cell line. J. Controlled Release, 54: 223-233, 1998.
28. Duncan, R., Coatsworth, J. K., and Burtles, S. Preclinical toxicology of a novel polymeric antitumour agent, HPMA copolymer-doxorubicin (PK1). Hum. Exp. Toxicol., 17: 93-104, 1998.
29. Cassidy, J., Paul, J., Soukop, M., Habeshaw, T., Reed, N. S., Parkin, D., and Kaye, S. B. Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother. Pharmacol., 44: 161-166, 1998.
30. Miller, A. B., Hoogstraten, S., Staquet, M., and Winkler, J. Reporting results of cancer treatment. Cancer (Phila.), 74: 207-214, 1981.
31. 131I-MIBG therapy for neuroblastoma in children. Br. J. Radiol., 68: 481-490, 1995.
32. Fraier, D., Frigerio, E., Pianezzola, E., Strolin-Benedetti, M., Cassidy, J., and Vasey, P. A. A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl)methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone, in human plasma and urine by reversed-phase HPLC with fluorimetric detection. J. Pharm. Biomed. Anal., 13: 625-633, 1995.
33. Beal, S. L., Sheiner, S. L., and Boeckman, A. J. NONMEM IV User's Guide, Parts I-IV. San Francisco: NONMEM Project Group, University of California, San Francisco, 1989-1994.
34. Forssen E. A., and Ross, M. E. DaunoXome treatment of solid tumours: preclinical and clinical investigations. J. Liposome Res., 4: 481, 1994.
35. Gill, P. S., Espina, B. M., Muggia, F., Cabriales, S., Tulpule, A., Esplin, J. A., Leibman, H. A., Forssen, E., Ross, M. E., and Levine, A. M. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J. Clin. Oncol., 13: 996-1003, 1995.
36. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Tamar, S., Cohen, R., Martin, F., Huang, A., and Barenholz, Y. Prolongation of the circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res., 54: 987-992, 1994.
37. Goebel, F-D., Goldstein, D., Goos, M., Jablonowski, H., and Stewart, J. S., for the International SL-DOX Study Group. Efficacy and safety of stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Br. J. Cancer, 73: 989-994, 1996.
38. Uziely, B., Jeffers, S., Isaacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., and Gabizon, A. Liposomal doxorubicin: antitumour activity and unique toxicities during two complementary Phase I studies. J. Clin. Oncol., 13: 1777-1785, 1995.
39. Duncan, R., Seymour, L. C. W., and Scarlett, L. Af-(2-Hydroxypropyl)methacrylamide copolymers with pendant galactosamine residues. Fate after intravenous administration to rats. Biochim. Biophys. Acta, 880: 62-71, 1986.
40. Ripamonti, M., Pezzoni, G., Pesenti, E., Pastori, A., Farao, M., Bargiotti, A., Suarato, A., Spreafico, F., and Grandi, M. In vivo antitumour activity of FCE-23765, a methoxymorpholino derivative of doxorubicin active on doxonibicin-resistant tumour cells. Br. J. Cancer, 65: 703-707, 1992.
41. Vasey, P. A., Bissett, D., Strolin-Benedetti, M., Poggessi, I., Breda, N., Adams, L., Wilson, P., Pacciarini, M. A., and Cassidy, J. Phase I clinical and pharmacokinetic study of (FCE 23762). Cancer Res., 55: 2090-2096, 1995.
42. Angelucci, F., Ballinari, D., and Farao, M. Synthesis and biological evaluation of polymer-bound 3′-deamino-3′-(2-methoxy-4-morpholinyl)doxorubicin. In: Proc. XIII International Symposia on Medicinal Chemistry, September 19-23, 1994. Paris.
43. Duncan, R., Seymour, L. W., O'Hare, K. B., Flanagan, P. A., Wedge, S., Hume, I. C., Ulbrich, K., Strohalm, J., Subr, V., Spreafico, F., Grandi, M., Ripamonti, M., Farao, M., and Suarato, A. Preclinical evaluation of polymer-bound doxorubicin. J. Controlled Release, 19: 331-346, 1992.